W
WAVEMAN · COMPANY
HEPA · Hepion Pharmaceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

HEPA

Hepion Pharmaceuticals, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001583771
CLUSTER · 5 INSIDERSACTIVIST 13DC-SUITE BUYING · 3☆ WATCH
INSIDER NET · 180D
$1.2M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
5
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$1.2M over 180 days
+$825.0K over 90 days · +$250.0K of it by a 10%+ holder
more than 90% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
<0.1% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
the lowest in Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
5 insiders independently bought a net $1.2M — no planned sales are queued against it.
Sireesh Appajosyula disclosed a 5%+ stake (5.7%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +0.0%
+0.0%12M
-47%-17%+14%+44%2025-092025-102025-122026-032026-052026-072026-09 2026-08-03 · LoPriore Vincent S bought $400.0K2026-04-21 · LoPriore Vincent S bought $200.0K2026-08-03 · LoPriore Vincent S bought $100.0K2026-08-03 · Appajosyula Sireesh bought $100.0K2026-08-03 · Purcell Michael J. bought $100.0K2026-08-03 · Stetz Gary S. bought $100.0K2026-04-21 · Purcell Michael J. bought $50.0K2026-04-21 · LoPriore Vincent S bought $50.0K2026-04-21 · Appajosyula Sireesh bought $50.0K2026-04-21 · Stetz Gary S. bought $50.0K2026-08-03 · Stetz Gary S. II bought $25.0K2026-08-20 · Sireesh Appajosyula filed a 5%+ stake (5.7%)2026-08-20 · Gary Stetz filed a 5%+ stake (5.7%)2026-08-07 · Black Global 5 LLC filed a 5%+ stake (11.1%)2026-08-07 · Red Global 3, LLC filed a 5%+ stake (11.1%)2026-08-07 · Darin Feinstein filed a 5%+ stake (11.1%)2026-05-01 · Gravitas Capital LP filed a 5%+ stake (17.17%)2026-05-01 · Invictus Capital Advisors Pension Plan filed a 5%+ stake (4.29%)2026-05-01 · Vincent LoPriore filed a 5%+ stake (21.46%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
5 insiders reported buying shares.
The record shows a net $1.2M bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Hepion Pharmaceuticals, Inc. insiders bought a net $1.2M of stock across 19 Form 4 purchases and sales, with 5 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
LoPriore Vincent S
Executive Chairman
BUY
2026-08-03
8,000,000.0
$400.0K
LoPriore Vincent S
Executive Chairman
BUY
2026-08-03
2,000,000.0
$100.0K
Appajosyula Sireesh
Chief Operating Officer
BUY
2026-08-03
2,000,000.0
$100.0K
Purcell Michael J.
Director
BUY
2026-08-03
2,000,000.0
$100.0K
Stetz Gary S.
Interim CEO
BUY
2026-08-03
2,000,000.0
$100.0K
19 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 14 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Ancora Advisors LLC
1.0 sh
$0
5%+ owners
13D = intent to influence · 13G = passive
Sireesh Appajosyula
ACTIVIST 13D · 2026-08-20
5.7%
Gary Stetz
ACTIVIST 13D · 2026-08-20
5.7%
Black Global 5 LLC
ACTIVIST 13D · 2026-08-07
11.1%
Red Global 3, LLC
ACTIVIST 13D · 2026-08-07
11.1%
Darin Feinstein
ACTIVIST 13D · 2026-08-07
11.1%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 2
0 ACTIVE
1
Early Phase 1
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE——$0$0
OPERATING INCOME$-4.2M$-19.3M$-48.4M$-45.5M
NET INCOME$-8.3M$-13.2M$-48.9M$-42.2M
EPS (DILUTED)-0.88-107.35-616.07-11.90
OPERATING CASH FLOW$-3.3M$-18.2M$-40.9M$-35.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →